Ocular Therapeutix
OCUL
68 hedge funds and large institutions have $99.9M invested in Ocular Therapeutix in 2019 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 24 increasing their positions, 15 reducing their positions, and 11 closing their positions.
90% more call options, than puts
Call options by funds: $1.23M | Put options by funds: $647K
60% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 15
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
18% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 11
13% more capital invested
Capital invested by funds: $88.6M → $99.9M (+$11.3M)
0.89% more ownership
Funds ownership: 52.11% → 53% (+0.89%)
0% more funds holding
Funds holding: 68 → 68 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$3.89M |
| 2 |
DAM
Deltec Asset Management
New York
|
+$2.19M |
| 3 |
Man Group
London,
United Kingdom
|
+$1.61M |
| 4 |
JP Morgan Chase
New York
|
+$1.02M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$868K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.26M |
| 2 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$2.84M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$1.14M |
| 4 |
Jennison Associates
New York
|
-$1M |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$688K |
OCUL Hedge Fund Activity: Q2 2019 in Review
68 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q2 2019, worth a combined $99.9M — up 13% from $88.6M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new OCUL positions and 11 closed out — a net gain of 2 holders — while 24 added to existing stakes and 15 trimmed.
The largest buyer was Opaleye Management, adding an estimated $3.89M. The largest seller was Fidelity Investments, cutting an estimated $4.26M.
- 68 institutional investors held Ocular Therapeutix (OCUL) as of Q2 2019, unchanged from Q1 2019.
- Funds reported $99.9M of Ocular Therapeutix stock for Q2 2019, up 13% quarter-over-quarter.
- 13 funds opened new Ocular Therapeutix positions in Q2 2019 and 11 closed out, a net change of +2 holders.
- The largest Ocular Therapeutix buyer in Q2 2019 was Opaleye Management, an estimated $3.89M added.
- The largest Ocular Therapeutix seller in Q2 2019 was Fidelity Investments, an estimated $4.26M sold.
Based on aggregated 13F filings for Q2 2019.